Who is sponsoring NCT01307332?

NCT01307332 is sponsored by University of British Columbia.

What drugs are being tested in NCT01307332?

Interventions in NCT01307332: MabCampath-1h.

What condition does NCT01307332 study?

NCT01307332 studies Relapsing Remitting Multiple Sclerosis.

Is NCT01307332 still recruiting?

NCT01307332 is currently completed. Last updated 12 October 2018.

Last reviewed 2018-10-12 · How we verify

NCT01307332: iCAMMS-IST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients

Completed Phase 3 Last updated 12 October 2018

What this trial tests

Phase 3 trial testing MabCampath-1h in Relapsing Remitting Multiple Sclerosis in 27 participants. Completed in 28 September 2018.

Timeline

1 March 2011

Primary endpoint
28 September 2018

28 September 2018

Quick facts

Lead sponsor	University of British Columbia
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	1 March 2011
Primary completion	28 September 2018
Estimated completion	28 September 2018
Sites	1 location across Canada

Drugs / interventions tested

MabCampath-1h — full drug profile →

Conditions studied

Relapsing Remitting Multiple Sclerosis — all drugs for Relapsing Remitting Multiple Sclerosis →

Sponsor

University of British Columbia

Who can join

Adults 18 to 50, any sex, with Relapsing Remitting Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Changes in normal appearing white matter from baseline through month 24.
Time frame: 24 months
The MRI study is designed to identify possible mechanisms by which alemtuzumab acts to protect the brain from inflammation and how it may enhance repair through remyelination.

Sponsor's own description

There are two parts to this investigator sponsored trial (IST): 1. To perform advanced serial MRI studies on patients initiating alemtuzumab therapy. 2. To provide serum samples for the University of Southern California (USC) ICAM125 lymphocyte recovery study.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Promoting remyelination in multiple sclerosis-recent advances.
Münzel EJ, Williams A. · · 2013 · cited 66× · PMID 24242317 · DOI 10.1007/s40265-013-0146-8
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W, Lund BT, Li P, Levy AM, et al · · 2020 · cited 44× · PMID 32539719 · DOI 10.1186/s12974-020-01847-9
Ultrashort echo time (UTE) magnetic resonance imaging of myelin: technical developments and challenges.
Ma YJ, Jang H, Chang EY, Hiniker A, et al · · 2020 · cited 31× · PMID 32550129 · DOI 10.21037/qims-20-541

Verify or expand the search:

Other recruiting trials for Relapsing Remitting Multiple Sclerosis

Currently open trials in the same condition.

NCT06796504 — The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study · NA · recruiting
NCT05949580 — Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple · recruiting
NCT06282081 — Serum Neurofilament Light in Multiple Sclerosis · active not recruiting
NCT05327322 — Functional Outcomes From Diets in Multiple Sclerosis · NA · active not recruiting
NCT05171972 — Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment · active not recruiting

Other University of British Columbia trials

Trials by the same sponsor.

NCT07340970 — Sensory Stimuli During Cesarean Delivery · not yet recruiting
NCT07481201 — Phenylalanine Requirements in the Menstrual Phases · NA · not yet recruiting
NCT07492095 — Leucine Requirements in School-Age Children · NA · not yet recruiting
NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01307332 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
Last refreshed: 12 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01307332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing